+

WO2001092542A8 - Vecteurs ciblant l'integrine avec activite de transfection accrue - Google Patents

Vecteurs ciblant l'integrine avec activite de transfection accrue

Info

Publication number
WO2001092542A8
WO2001092542A8 PCT/GB2001/002394 GB0102394W WO0192542A8 WO 2001092542 A8 WO2001092542 A8 WO 2001092542A8 GB 0102394 W GB0102394 W GB 0102394W WO 0192542 A8 WO0192542 A8 WO 0192542A8
Authority
WO
WIPO (PCT)
Prior art keywords
integrin
transfection activity
targeting vectors
enhanced transfection
glycine
Prior art date
Application number
PCT/GB2001/002394
Other languages
English (en)
Other versions
WO2001092542A3 (fr
WO2001092542A2 (fr
Inventor
Stephen Lewis Hart
Original Assignee
Ich Productions Ltd
Stephen Lewis Hart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0013090A external-priority patent/GB0013090D0/en
Priority claimed from GB0013089A external-priority patent/GB0013089D0/en
Application filed by Ich Productions Ltd, Stephen Lewis Hart filed Critical Ich Productions Ltd
Priority to AU2001260467A priority Critical patent/AU2001260467A1/en
Publication of WO2001092542A2 publication Critical patent/WO2001092542A2/fr
Publication of WO2001092542A3 publication Critical patent/WO2001092542A3/fr
Publication of WO2001092542A8 publication Critical patent/WO2001092542A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne un complexe qui possède une activité de transfection accrue. Ce complexe comprend: i) un acide nucléique; ii) un composant qui se lie à l'intégrine; iii) un composant qui se lie à un acide nucléique polycationique, tel qu'une olygolysine; et iv) un composant lipidique tel qu'un liposome cationique dans lequel complexe le composant qui se lie à l'intégrine comprend un élément qui se lie à l'intégrine et un élément d'espacement, cet élément d'espacement étant plus long et/ou plus hydrophobe que les espaceurs dipeptidiques GG (glycine-glycine) et GA (glycine-alanine).
PCT/GB2001/002394 2000-05-30 2001-05-30 Vecteurs ciblant l'integrine avec activite de transfection accrue WO2001092542A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001260467A AU2001260467A1 (en) 2000-05-30 2001-05-30 Integrin-targeting vectors having enhanced transfection activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0013089.8 2000-05-30
GB0013090A GB0013090D0 (en) 2000-05-30 2000-05-30 Intergrin-targetting vectors having enhanced transfection activity
GB0013089A GB0013089D0 (en) 2000-05-30 2000-05-30 Improved methods of transfection
GB0013090.6 2000-05-30
US28741001P 2001-05-01 2001-05-01
US60/287,410 2001-05-01

Publications (3)

Publication Number Publication Date
WO2001092542A2 WO2001092542A2 (fr) 2001-12-06
WO2001092542A3 WO2001092542A3 (fr) 2003-05-30
WO2001092542A8 true WO2001092542A8 (fr) 2003-12-24

Family

ID=27255741

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2001/002396 WO2001092543A2 (fr) 2000-05-30 2001-05-30 Procede ameliore de transfection
PCT/GB2001/002394 WO2001092542A2 (fr) 2000-05-30 2001-05-30 Vecteurs ciblant l'integrine avec activite de transfection accrue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002396 WO2001092543A2 (fr) 2000-05-30 2001-05-30 Procede ameliore de transfection

Country Status (5)

Country Link
EP (1) EP1285081A2 (fr)
JP (1) JP2003534804A (fr)
AU (2) AU2001258659A1 (fr)
CA (1) CA2410419A1 (fr)
WO (2) WO2001092543A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268668B2 (en) 2003-05-09 2007-09-11 American Express Travel Related Services Company, Inc. Systems and methods for managing multiple accounts on a RF transaction instrument
CA2449054C (fr) * 2001-05-30 2011-01-04 The Scripps Research Institute Liposome de ciblage d'integrine pour liberation d'acide nucleique
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
FR2860236B1 (fr) * 2003-09-25 2006-01-06 Theraptosis Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique
EP2252627B1 (fr) 2008-01-24 2017-04-19 Esperance Pharmaceuticals Produits de fusion recombinants à domaine lytique et leurs procédés de fabrication et d'utilisation
US20190336608A1 (en) * 2016-06-09 2019-11-07 Curevac Ag Cationic carriers for nucleic acid delivery
EP3468613A1 (fr) 2016-06-09 2019-04-17 CureVac AG Supports hybrides pour cargo d'acides nucléiques

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067183A1 (fr) * 1989-09-27 1991-03-28 Lee L. Rubin Composition pour l'inhibition de l'adhesion cellulaire et methode d'utilisation
JPH07505283A (ja) * 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1997033605A1 (fr) * 1996-03-15 1997-09-18 Yale University Occludine humaine, ses utilisations et amelioration de l'absorption de medicaments a l'aide d'inhibiteurs d'occludine
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
WO1999040214A2 (fr) * 1998-02-09 1999-08-12 Genzyme Corporation Vehicules d'apport d'acide nucleique
AU4089899A (en) * 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
WO2000062815A2 (fr) * 1999-04-15 2000-10-26 Glaxo Group Limited Nouvelle composition pharmaceutique utilisable en therapie genique

Also Published As

Publication number Publication date
AU2001258659A1 (en) 2001-12-11
AU2001260467A1 (en) 2001-12-11
JP2003534804A (ja) 2003-11-25
CA2410419A1 (fr) 2001-12-06
EP1285081A2 (fr) 2003-02-26
WO2001092542A3 (fr) 2003-05-30
WO2001092542A2 (fr) 2001-12-06
WO2001092543A3 (fr) 2002-09-12
WO2001092543A2 (fr) 2001-12-06

Similar Documents

Publication Publication Date Title
AU7667398A (en) Integrin-targeting vectors having transfection activity
ZA983148B (en) Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA.
WO2001018681A8 (fr) Systeme de selection, de distribution et vente de polices de caracteres
AU2001288581A1 (en) Multi-mode smart card, system and associated methods
ZA981762B (en) Nucleic acid molecules encoding enzymes having fructosyl polymerase activity.
AU3143795A (en) Isoamylase gene from flaviobacterium sp., compositions containing it and methods using it
WO1997021826A3 (fr) Systemes de vecteurs adenoviraux et de lignees cellulaires complementaires
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
AU2001242790A1 (en) Data distribution server, terminal, and data distribution system
AU7908298A (en) Endo-beta-1,4-glucanases from (saccharothrix)
AU6059699A (en) Synthetic peptides, conjugation reagents and methods
HK1017134A1 (en) Electromagnetic relay, joining structure for hingespring and yoke in the electromagnetic relay.
ZA996813B (en) Process, system and computer readable medium for providing a prepaid fuel card and using a personal identification as a prepaid card.
AU5906699A (en) (neisseria spp.) polypeptide, nucleic acid sequence and uses thereof
WO2001092542A8 (fr) Vecteurs ciblant l'integrine avec activite de transfection accrue
AU8620698A (en) Antifreeze proteins, dna and expression systems
WO1996002650A3 (fr) Adn, produits de recombinaison, cellules et plantes derivees de celles-ci
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
EP1097646A3 (fr) Préparation à base de poudre de lait modifié
AU2002213452A1 (en) Applicator, e.g. for shaving preparations and the like
AU1818399A (en) Novel flea epoxide hydrolase nucleic acid molecules, proteins and uses thereof
AU2000249534A1 (en) Order receiving system, information providing unit, order receiving unit and recording medium
AU6346200A (en) Fault tolerant and combinatorial software environment system, method and medium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
CFP Corrected version of a pamphlet front page

Free format text: PUBLISHED FIGURE DELETED

NENP Non-entry into the national phase in:

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载